Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1016/j.eururo.2010.06.039. Epub 2010 Jul 9.
Affiliations
- PMID: 20637539
- DOI: 10.1016/j.eururo.2010.06.039
Randomized Controlled Trial
Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test
Monique J Roobol et al. Eur Urol. 2010 Oct.
Abstract
Background: The performance characteristics of serum prostate-specific antigen (PSA) as a diagnostic test for prostate cancer (PCa) are poor. The performance of the PCa antigen 3 (PCA3) gene as a primary diagnostic is unknown.
Objective: Assess the value of PCA3 as a first-line diagnostic test.
Design, setting and participants: Participants included men aged 63-75 who were invited for rescreening in the period from September 2007 to February 2009 within the European Randomised Study of Screening for Prostate Cancer, Rotterdam section.
Interventions: Lateral sextant biopsies were performed if the serum PSA value was > or =3.0 ng/ml and/or the PCA3 score was > or =10.
Measurements: Measurements included distribution and correlation of PSA value and PCA3 score and their relation to the number of cases and the characteristics of PCa detected. Additional value of PCA3 was included in men with previous negative biopsy and/or PSA <3.0 ng/ml.
Results and limitations: In 721 men, all biopsied, 122 PCa cases (16.9%) were detected. Correlation between PSA and PCA3 is poor (Spearman rank correlation: ρ=0.14; p<0.0001). A PSA > or =3.0 ng/ml misses 64.7% of the total PCa that can be detected with the sextant biopsy technique and 57.9% of serious PCa (T2a or higher and/or Gleason grade > or =4, n=19), and 68.2% of biopsies could have been avoided; the respective data for PCA3 > or =35 are 32%, 26.3%, and 51.7%. Performance of PCA3 in men with low PSA (area under the curve [AUC]: 0.63) and/or previous negative biopsy (AUC: 0.68) is unclear but has limited reliability due to small numbers.
Conclusions: PCA3 as a first-line screening test shows improvement of the performance characteristics and identification of serious disease compared with PSA in this prescreened population.
Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
- The role of the prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening.
Ficarra V, Novara G, Zattoni F. Ficarra V, et al. Eur Urol. 2010 Oct;58(4):482-4; discussion 484-5. doi: 10.1016/j.eururo.2010.07.025. Epub 2010 Jul 30. Eur Urol. 2010. PMID: 20685032 No abstract available.
Similar articles
- Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
Roobol MJ, Schröder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, van Leeuwen PJ. Roobol MJ, et al. Eur Urol. 2010 Dec;58(6):893-9. doi: 10.1016/j.eururo.2010.09.030. Epub 2010 Sep 26. Eur Urol. 2010. PMID: 20933321 Clinical Trial. - The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance.
van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA. van Gils MP, et al. Clin Cancer Res. 2007 Feb 1;13(3):939-43. doi: 10.1158/1078-0432.CCR-06-2679. Clin Cancer Res. 2007. PMID: 17289888 - PCA3: from basic molecular science to the clinical lab.
Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H. Day JR, et al. Cancer Lett. 2011 Feb 1;301(1):1-6. doi: 10.1016/j.canlet.2010.10.019. Epub 2010 Nov 18. Cancer Lett. 2011. PMID: 21093148 Review. - Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H. Auprich M, et al. Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25. Eur Urol. 2011. PMID: 21871709 Review.
Cited by
- Risk-based prostate cancer screening.
Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schröder FH, Vickers AJ. Zhu X, et al. Eur Urol. 2012 Apr;61(4):652-61. doi: 10.1016/j.eururo.2011.11.029. Epub 2011 Nov 24. Eur Urol. 2012. PMID: 22134009 Free PMC article. Review. - Beyond PSA: the next generation of prostate cancer biomarkers.
Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Prensner JR, et al. Sci Transl Med. 2012 Mar 28;4(127):127rv3. doi: 10.1126/scitranslmed.3003180. Sci Transl Med. 2012. PMID: 22461644 Free PMC article. Review. - Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies.
Steuber T, Tennstedt P, Macagno A, Athanasiou A, Wittig A, Huber R, Golding B, Schiess R, Gillessen S. Steuber T, et al. BJU Int. 2019 May;123(5):826-833. doi: 10.1111/bju.14540. Epub 2018 Oct 11. BJU Int. 2019. PMID: 30216634 Free PMC article. - Correlation of NTRK1 Downregulation with Low Levels of Tumor-Infiltrating Immune Cells and Poor Prognosis of Prostate Cancer Revealed by Gene Network Analysis.
Bagherabadi A, Hooshmand A, Shekari N, Singh P, Zolghadri S, Stanek A, Dohare R. Bagherabadi A, et al. Genes (Basel). 2022 May 8;13(5):840. doi: 10.3390/genes13050840. Genes (Basel). 2022. PMID: 35627227 Free PMC article. - Diagnostic value of urine prostate cancer antigen 3 test using a cutoff value of 35 μg/L in patients with prostate cancer.
Hu B, Yang H, Yang H. Hu B, et al. Tumour Biol. 2014 Sep;35(9):8573-80. doi: 10.1007/s13277-014-2109-4. Epub 2014 May 27. Tumour Biol. 2014. PMID: 24863945 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous